VVT Med Inc.
VVTM.V
Toronto Stock Exchange Ventures0.20
CAD
- -
- -
VVT Med Inc.
VVTM.V
(Toronto Stock Exchange Ventures)
Recent
price
0.20
P/E
ratio
- -
div
yld
- -
ROIC.AI
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- Similar Companies
- Business
- VVT Med Inc. develops, manufactures and distributes minimally invasive, non-thermal and non-tumescent medical-device solutions for the treatment of venous disease, initially targeting varicose veins and related medical and aesthetic indications. The Company’s principal catheter-based products comprise ScleroSafe®, a catheter-directed sclerotherapy and foam-delivery platform that combines simultaneous sclerosant injection and blood aspiration to treat a broad range of vein diameters, including reticular and spider veins under its expanded U.S. FDA 510(k) clearance; and V-Block™, a catheter-based venous-treatment system designed for office-based procedures. Its products are intended to enable anesthesia-free treatment with limited downtime, pain and side effects for vascular surgeons, phlebologists, interventional radiologists and other vein-care providers. ScleroSafe® and V-Block™ are FDA-cleared and CE-marked technologies, and the Company maintains a patented technology portfolio comprising 55 patents in 14 patent families across 20 countries, with protection extending through 2038. VVT Med conducts commercial activities internationally through direct and distributor-led channels, including the United States, Italy, Vatican City, San Marino, Greece, Portugal, the Dominican Republic, India and Sri Lanka. The Company is headquartered in Vancouver, British Columbia, Canada, and operates through wholly owned Israeli subsidiary VVT Med Ltd., which is based in Kfar Saba, Israel and serves as the legal manufacturer of its devices. Recent developments include the completion in September 2026 of the second tranche of a non-brokered private placement, bringing aggregate proceeds from the first two tranches to CAD1.89 million; conversion of CAD212,939.76 of vendor debt into common shares; and the appointment of Dermworks as exclusive trial distributor for ScleroSafe® in Portugal. During 2026, VVT Med also entered five-year exclusive ScleroSafe® distribution agreements with Uber Ros S.p.A. for Italy, Vatican City and San Marino, with approximately CAD2.3 million of potential minimum purchase commitments, and with General Chemical Products S.A. for Greece; appointed Antilles Medical as exclusive trial distributor in the Dominican Republic; reported initial patient treatments using ScleroSafe® in Italy; and expanded the regulatory indication for its next-generation ScleroSafe® foam-delivery system to include reticular and spider veins.